# Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

> **NCT07007052** · PHASE2 · NOT_YET_RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 33 (estimated)

## Conditions studied

- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Tagraxofusp

## Key facts

- **NCT ID:** NCT07007052
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2031-09-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007052, "Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07007052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*